Free Newsletter
FEATURES >> The most interesting logos in Pharma
J&J freezes salaries, cuts bonus targets
The compensation makeover has made its way to Johnson & Johnson. The company is freezing some employee salaries and lowering the maximum performance bonuses for 38 percent of its workforce, the Wall Street Journal reports.
But the pay cuts aren't about saving money, a spokeswoman told the Wall Street Journal. It's about standardizing compensation so that employees have an easier time moving around within the multinational, diversified company; plus, it will bring U.S. bonuses more in line with the market. "This program is about creating a global compensation program that is consistent and equitable for our employees across the company," the spokeswoman said.
Some bonus targets will actually increase--for 27 percent of J&J's 115,000 employees--and others will stay the same. Stock bonuses will take the biggest hit, a company announcement stated.
As you know, J&J isn't the only Big Pharma that's holding the line on pay. Bristol-Myers Squibb recently froze salaries for this year, for all employees except those whose pay increases are required by contract.
- read the WSJ story
- see the piece at The Street
Related Articles:
J&J sales up; profits down on charges
Johnson & Johnson - Top 10 Layoffs of 2009
Where will J&J's layoffs hit hardest?
J&J restructuring claims up to 8,000 jobs
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities



SHARE
WITH: